It is sad. You would think that being the first drug ever for psychosis linked to Parkinson's disease would have some decent, national news coverage. No, nada, not a peep from CNN, NYTimes, LATimes, or even the local San Diego online news. This means as of today, the great majority of Americans still don't know about this drug. If I were a doctor, nurse and care taker who specialize in PDP, I would still not have heard or become aware of this new drug just got approved yesterday. I guess may be it is too much to ask for nationwide news coverage. After all news coverage like that is worth millions of marketing dollars. Acad, if they really want to launch the drug in Jun, then what they need is ad's, lots of it. and not just hiring and training sales reps. They need to spend some serious dollars to bring ads to newspaper, magazine, Facebook ads, or TV commercials (i.e. NBA Playoffs). They only have a month before launch; so let's see some ad's. General public including physicians need to develop awareness of the drug to create demands. Ads, Ads, Ads!
I think it is fair to say that FDA approval is a done deal; but sadly there won't be big short squeeze to run up share price. I forecast 31 to 32 at the most by May 1 and then 35 to 36 peak before sell on news brings it down to 31 after FDA approval. It will slowly drop to mid to high 20's. Why you ask? Shorts know ACAD is really no longer a developmental or clinical trial company. There stock price is now entering the next phase. A phase where where value is entirely based on the competency, experience and know how to produce, market, sell, and distribute the drug plus education to doctors and getting insurance coverage. On top of all that, sales from each quarter needs to show growth. If ACAD doesn't live up to this level of performance, shorts will zerg this stock to half a billion. The talk of partnership or buyout is premature; big pharmas all want to know if the drug works in real world before they can see the full revenue potential. After all there is no approved drugs like this. Longs have plenty of challenges ahead and shorts will zerg any chance they get.